A Phase 3 interventional study of Baloxavir Marboxil and Placebo to Baloxavir Marboxil in Influenza, sponsored by Shionogi. Completed. Open to participants aged 12 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-05-08.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.
Among the 18 studies testing baloxavir in Influenza, Human, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 2nd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
Dre Pauline Vetter · Sites in Switzerland
Ages 18+
Hoffmann-La Roche · Sites in United States, Bulgaria, Poland and 1 more country
Ages 3 wk–11 yrs
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
By country, each count listing its studies:
baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 12 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 13 · Phase 4 3
First in 2016; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,436 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 483 across the 18 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 8 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies testing baloxavir in Influenza, Human that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06653569Phase 3Dre Pauline VetterEfficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | 2027-04 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing baloxavir in Influenza, Human, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a diagnosis of influenza virus infection confirmed by all of the following:
At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater
At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater
The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:
Exclusion Criteria:
Patients with any of the following risk factors
Women who are breastfeeding or have a positive pregnancy test in the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test in the predose examinations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
Drug: Baloxavir Marboxil · Drug: Placebo to Oseltamivir
Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
Drug: Placebo to Baloxavir Marboxil · Drug: Oseltamivir
Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
Drug: Placebo to Baloxavir Marboxil · Drug: Placebo to Oseltamivir
Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
Drug: Baloxavir Marboxil
Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
Drug: Placebo to Baloxavir Marboxil
2 to4 X 20-mg tablets taken orally
Also known as: S-033188
2 to4 X 20-mg tablets taken orally
75 mg capsules taken orally
Also known as: Tamiflu®
Placebo capsules matching oseltamivir 75 mg capsules
Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.
Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.
Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo
Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.
Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.
Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).
Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
Time frame: Day 1 to Day 9
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
Time frame: Day 1 to Day 9
Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
Time frame: Day 1 to Day 9
Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
Time frame: Day 1 to Day 9
Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
Time frame: Day 1 to Day 9
Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
Time frame: Day 1 to Day 9
Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
Time frame: Day 1 to Day 9
Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
Time frame: Day 1 to Day 9
Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .
Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .
Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Time frame: Initiation of study treatment up to Day 14
Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.
Time frame: Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.
Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.
Time frame: Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.
Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
Time frame: Initiation of study treatment up to Day 14
Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
Time frame: Initiation of study treatment up to Day 14
Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo
Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment
Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo
Participant's self-measured axillary temperature using an electronic thermometer.
Time frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir
Participant's self-measured axillary temperature using an electronic thermometer.
Time frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time frame: Initiation of study treatment up to Day 14
Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time frame: Initiation of study treatment up to Day 14
Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
Time frame: Initiation of study treatment up to Day 14
Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
Time frame: Initiation of study treatment up to Day 14
Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo
The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
Time frame: Initiation of study treatment up to Day 14
Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir
The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
Time frame: Initiation of study treatment up to Day 14
Percentage of Participants With Adverse Events (AEs)
Time frame: From first dose of study drug to Day 22
This study was conducted at 297 sites, consisting of 141 sites in Japan, 149 sites in the United States, and 7 sites in Canada. Participants were enrolled from December 2016 to April 2017.
| Milestone | Baloxavir | Placebo | Oseltamivir |
|---|---|---|---|
| Started | 612 | 310 | 514 |
| Received study drug | 610 | 309 | 513 |
| Intention to treat infected population | 456 | 231 | 377 |
| Completed | 578 | 290 | 498 |
| Not completed | 34 | 20 | 16 |
| Withdrew: Adverse event | 2 | 2 | 4 |
| Withdrew: Failure to meet eligibility criteria | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 17 | 9 | 11 |
| Withdrew: Lost to follow-up | 12 | 5 | 0 |
| Withdrew: Miscellaneous | 2 | 2 | 1 |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo | 53.7 (49.5 to 58.5) | 80.2 (72.6 to 87.1) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir | 53.5 (48.0 to 58.5) | 53.8 (50.2 to 56.4) |
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.
| percentage of participants | Baloxavir | Placebo |
|---|---|---|
| Day 2 | 47.6 (42.7 to 52.5) | 96.0 (92.3 to 98.3) |
| Day 3 | 21.7 (17.8 to 26.0) | 70.5 (63.5 to 76.8) |
| Day 4 | 16.7 (10.3 to 24.8) | 56.1 (42.4 to 69.3) |
| Day 5 | 13.5 (10.4 to 17.3) | 29.7 (23.3 to 36.7) |
| Day 6 | 8.2 (3.6 to 15.6) | 12.5 (4.7 to 25.2) |
| Day 9 | 2.9 (1.5 to 5.1) | 4.6 (2.1 to 8.5) |
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.
| percentage of participants | Baloxavir | Oseltamivir |
|---|---|---|
| Day 2 | 47.4 (41.9 to 52.8) | 91.1 (87.6 to 93.9) |
| Day 3 | 20.0 (15.8 to 24.7) | 57.3 (51.9 to 62.6) |
| Day 4 | 16.1 (9.1 to 25.5) | 27.6 (19.3 to 37.2) |
| Day 5 | 12.9 (9.5 to 17.0) | 20.8 (16.6 to 25.6) |
| Day 6 | 5.6 (1.6 to 13.8) | 9.0 (3.7 to 17.6) |
| Day 9 | 3.0 (1.4 to 5.4) | 3.2 (1.6 to 5.7) |
Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.
| percentage of participants | Baloxavir | Placebo |
|---|---|---|
| Day 2 | 97.3 (95.3 to 98.6) | 97.7 (94.8 to 99.3) |
| Day 3 | 95.6 (93.3 to 97.4) | 97.2 (94.0 to 99.0) |
| Day 4 | 93.4 (87.5 to 97.1) | 91.0 (81.5 to 96.6) |
| Day 5 | 87.4 (83.9 to 90.4) | 93.9 (89.8 to 96.7) |
| Day 6 | 74.8 (65.2 to 82.8) | 77.2 (64.2 to 87.3) |
| Day 9 | 61.5 (56.7 to 66.1) | 72.4 (65.9 to 78.2) |
Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.
| percentage of participants | Baloxavir | Oseltamivir |
|---|---|---|
| Day 2 | 97.3 (95.0 to 98.7) | 98.6 (96.8 to 99.6) |
| Day 3 | 95.3 (92.5 to 97.2) | 97.5 (95.3 to 98.9) |
| Day 4 | 93.6 (86.6 to 97.6) | 93.0 (86.8 to 96.9) |
| Day 5 | 86.6 (82.6 to 89.9) | 92.1 (88.7 to 94.7) |
| Day 6 | 69.3 (57.6 to 79.5) | 80.7 (70.6 to 88.6) |
| Day 9 | 60.2 (54.9 to 65.3) | 64.7 (59.5 to 69.7) |
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
| log₁₀[TCID₅₀/mL] | Baloxavir | Placebo |
|---|---|---|
| Day 2 | -4.45 ± 2.03 | -1.19 ± 2.43 |
| Day 3 | -4.82 ± 1.99 | -2.88 ± 2.88 |
| Day 4 | -4.50 ± 2.02 | -3.31 ± 2.34 |
| Day 5 | -4.95 ± 1.93 | -4.47 ± 2.21 |
| Day 6 | -4.58 ± 1.99 | -4.68 ± 2.12 |
| Day 9 | -5.06 ± 1.87 | -4.87 ± 1.85 |
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
| log₁₀[TCID₅₀/mL] | Baloxavir | Oseltamivir |
|---|---|---|
| Day 2 | -4.39 ± 2.07 | -2.53 ± 2.03 |
| Day 3 | -4.79 ± 2.03 | -4.20 ± 2.02 |
| Day 4 | -4.46 ± 2.03 | -4.63 ± 1.89 |
| Day 5 | -4.95 ± 1.94 | -4.98 ± 1.81 |
| Day 6 | -4.56 ± 1.99 | -4.85 ± 1.95 |
| Day 9 | -5.03 ± 1.89 | -5.22 ± 1.70 |
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).
| log₁₀ virus particles/mL | Baloxavir | Placebo |
|---|---|---|
| Day 2 | -1.63 ± 1.03 | -0.56 ± 1.37 |
| Day 3 | -2.80 ± 1.20 | -1.61 ± 1.76 |
| Day 4 | -3.07 ± 1.59 | -1.95 ± 1.76 |
| Day 5 | -3.75 ± 1.47 | -3.04 ± 1.62 |
| Day 6 | -3.83 ± 1.64 | -3.03 ± 1.85 |
| Day 9 | -4.43 ± 1.42 | -4.06 ± 1.47 |
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
| log₁₀ virus particles/mL | Baloxavir | Oseltamivir |
|---|---|---|
| Day 2 | -1.61 ± 1.06 | -1.10 ± 1.10 |
| Day 3 | -2.79 ± 1.21 | -2.44 ± 1.24 |
| Day 4 | -2.94 ± 1.62 | -2.97 ± 1.29 |
| Day 5 | -3.76 ± 1.44 | -3.62 ± 1.34 |
| Day 6 | -3.81 ± 1.52 | -3.88 ± 1.35 |
| Day 9 | -4.43 ± 1.43 | -4.52 ± 1.22 |
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
| log₁₀[TCID₅₀/mL]*hours | Baloxavir | Placebo |
|---|---|---|
| Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo | -836.2 ± 348.9 | -641.8 ± 377.6 |
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
| log₁₀[TCID₅₀/mL]*hours | Baloxavir | Oseltamivir |
|---|---|---|
| Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir | -829.6 ± 350.3 | -790.2 ± 328.4 |
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
| log₁₀ virus particles/mL*hours | Baloxavir | Placebo |
|---|---|---|
| Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo | -582.0 ± 230.9 | -456.8 ± 269.6 |
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
| log₁₀ virus particles/mL*hours | Baloxavir | Oseltamivir |
|---|---|---|
| Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir | -581.0 ± 231.2 | -569.7 ± 228.8 |
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo | 24.0 (24.0 to 48.0) | 96.0 (NA to NA) |
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir | 24.0 (24.0 to 48.0) | 72.0 (72.0 to 96.0) |
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo | 216.0 (216.0 to 240.0) | 240.0 (240.0 to 336.0) |
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir | 216.0 (192.0 to 240.0) | 240.0 (216.0 to 240.0) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .
| percentage of participants | Baloxavir | Placebo |
|---|---|---|
| 12 hours | 9.7 (6.9 to 13.1) | 8.1 (4.7 to 12.9) |
| 24 hours | 23.1 (19.3 to 27.3) | 12.8 (8.7 to 18.0) |
| 36 hours | 42.4 (37.2 to 47.7) | 23.1 (17.4 to 29.6) |
| 48 hours | 50.7 (45.9 to 55.4) | 26.4 (20.7 to 32.7) |
| 72 hours | 68.9 (64.3 to 73.3) | 49.5 (42.7 to 56.4) |
| 96 hours | 78.6 (74.4 to 82.3) | 69.9 (63.3 to 75.9) |
| 120 hours | 85.5 (81.8 to 88.8) | 81.6 (75.7 to 86.6) |
| 144 hours | 89.1 (85.7 to 92.0) | 85.4 (79.7 to 90.0) |
| 168 hours | 91.6 (88.4 to 94.1) | 88.3 (83.0 to 92.5) |
| 192 hours | 90.9 (87.7 to 93.5) | 91.4 (86.5 to 94.9) |
| 216 hours | 91.1 (86.5 to 94.5) | 91.9 (85.2 to 96.2) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .
| percentage of participants | Baloxavir | Oseltamivir |
|---|---|---|
| 12 hours | 8.7 (5.8 to 12.4) | 4.9 (2.7 to 7.9) |
| 24 hours | 21.3 (17.2 to 25.9) | 22.7 (18.5 to 27.4) |
| 36 hours | 41.1 (35.5 to 46.9) | 38.7 (33.1 to 44.5) |
| 48 hours | 51.0 (45.7 to 56.2) | 54.4 (49.1 to 59.7) |
| 72 hours | 70.7 (65.6 to 75.4) | 73.0 (68.1 to 77.5) |
| 96 hours | 79.8 (75.2 to 83.9) | 80.5 (76.0 to 84.5) |
| 120 hours | 86.1 (82.0 to 89.6) | 87.0 (82.9 to 90.3) |
| 144 hours | 89.2 (85.4 to 92.3) | 91.3 (87.8 to 94.1) |
| 168 hours | 91.4 (87.8 to 94.1) | 94.3 (91.3 to 96.5) |
| 192 hours | 90.8 (87.2 to 93.7) | 95.5 (92.6 to 97.4) |
| 216 hours | 90.9 (85.8 to 94.6) | 96.3 (92.5 to 98.5) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo | 33.8 (31.0 to 38.3) | 53.5 (45.9 to 57.3) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours. Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir | 36.7 (32.0 to 40.1) | 37.4 (31.5 to 42.4) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo | 46.0 (43.4 to 50.6) | 69.1 (63.9 to 78.1) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir | 46.0 (42.7 to 52.0) | 44.6 (40.6 to 49.5) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.
| scores on a scale | Baloxavir | Placebo |
|---|---|---|
| 12 hours | -2.4 ± 0.2 | -2.5 ± 0.3 |
| 24 hours | -4.7 ± 0.2 | -3.6 ± 0.3 |
| 36 hours | -6.7 ± 0.2 | -4.9 ± 0.3 |
| 48 hours | -7.8 ± 0.2 | -6.0 ± 0.3 |
| 72 hours | -9.4 ± 0.2 | -8.0 ± 0.2 |
| 96 hours | -10.5 ± 0.2 | -9.5 ± 0.2 |
| 120 hours | -10.9 ± 0.2 | -10.6 ± 0.2 |
| 144 hours | -11.6 ± 0.1 | -11.2 ± 0.2 |
| 168 hours | -11.9 ± 0.1 | -11.8 ± 0.2 |
| 192 hours | -12.0 ± 0.1 | -12.0 ± 0.2 |
| 216 hours | -12.4 ± 0.2 | -12.4 ± 0.3 |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.
| scores on a scale | Baloxavir | Oseltamivir |
|---|---|---|
| 12 hours | -2.2 ± 0.2 | -2.4 ± 0.2 |
| 24 hours | -4.5 ± 0.2 | -4.7 ± 0.2 |
| 36 hours | -6.5 ± 0.2 | -6.3 ± 0.2 |
| 48 hours | -7.6 ± 0.2 | -7.8 ± 0.2 |
| 72 hours | -9.6 ± 0.2 | -9.7 ± 0.2 |
| 96 hours | -10.5 ± 0.2 | -10.6 ± 0.2 |
| 120 hours | -11.0 ± 0.2 | -11.3 ± 0.2 |
| 144 hours | -11.8 ± 0.2 | -11.8 ± 0.2 |
| 168 hours | -11.9 ± 0.2 | -12.1 ± 0.2 |
| 192 hours | -12.0 ± 0.1 | -12.4 ± 0.2 |
| 216 hours | -12.4 ± 0.2 | -12.5 ± 0.2 |
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo | 24.5 (22.6 to 26.6) | 42.0 (37.4 to 44.6) |
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir | 24.4 (22.2 to 26.5) | 24.0 (22.1 to 25.9) |
Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
| percentage of participants | Baloxavir | Placebo |
|---|---|---|
| 12 hours | 26.5 (22.3 to 30.9) | 25.3 (19.7 to 31.7) |
| 24 hours | 64.3 (59.6 to 68.7) | 48.4 (41.8 to 55.2) |
| 36 hours | 80.8 (76.8 to 84.5) | 58.3 (51.4 to 64.9) |
| 48 hours | 89.3 (86.0 to 92.0) | 67.3 (60.6 to 73.4) |
| 72 hours | 93.7 (90.9 to 95.8) | 83.8 (77.8 to 88.6) |
| 96 hours | 92.8 (89.8 to 95.1) | 93.9 (89.6 to 96.8) |
| 120 hours | 92.9 (89.8 to 95.2) | 92.8 (88.2 to 96.0) |
| 144 hours | 93.4 (90.4 to 95.7) | 93.6 (89.1 to 96.6) |
| 168 hours | 93.3 (90.3 to 95.6) | 93.6 (89.1 to 96.6) |
| 192 hours | 94.1 (91.2 to 96.3) | 93.7 (89.3 to 96.7) |
| 216 hours | 92.5 (89.3 to 94.9) | 92.7 (88.0 to 95.9) |
Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.
| percentage of participants | Baloxavir | Oseltamivir |
|---|---|---|
| 12 hours | 25.0 (20.6 to 29.8) | 28.3 (23.7 to 33.3) |
| 24 hours | 64.3 (59.1 to 69.2) | 66.8 (61.7 to 71.6) |
| 36 hours | 81.9 (77.5 to 85.8) | 79.1 (74.5 to 83.2) |
| 48 hours | 90.1 (86.5 to 93.0) | 89.9 (86.3 to 92.8) |
| 72 hours | 93.8 (90.7 to 96.1) | 89.5 (85.8 to 92.6) |
| 96 hours | 93.9 (90.8 to 96.2) | 94.9 (92.0 to 97.0) |
| 120 hours | 93.8 (90.6 to 96.2) | 95.8 (93.1 to 97.7) |
| 144 hours | 92.8 (89.4 to 95.4) | 94.5 (91.5 to 96.7) |
| 168 hours | 93.6 (90.3 to 96.1) | 95.9 (93.0 to 97.8) |
| 192 hours | 94.6 (91.4 to 96.8) | 95.8 (92.9 to 97.7) |
| 216 hours | 92.8 (89.3 to 95.4) | 94.5 (91.3 to 96.8) |
Participant's self-measured axillary temperature using an electronic thermometer.
| °C | Baloxavir | Placebo |
|---|---|---|
| 12 hours | 37.40 ± 0.05 | 37.49 ± 0.07 |
| 24 hours | 36.73 ± 0.04 | 37.07 ± 0.05 |
| 36 hours | 36.49 ± 0.04 | 36.90 ± 0.05 |
| 48 hours | 36.32 ± 0.03 | 36.69 ± 0.05 |
| 72 hours | 36.26 ± 0.03 | 36.48 ± 0.04 |
| 96 hours | 36.27 ± 0.03 | 36.31 ± 0.04 |
| 120 hours | 36.28 ± 0.03 | 36.25 ± 0.04 |
Participant's self-measured axillary temperature using an electronic thermometer.
| °C | Baloxavir | Oseltamivir |
|---|---|---|
| 12 hours | 37.47 ± 0.05 | 37.35 ± 0.05 |
| 24 hours | 36.78 ± 0.04 | 36.73 ± 0.04 |
| 36 hours | 36.55 ± 0.04 | 36.54 ± 0.04 |
| 48 hours | 36.34 ± 0.03 | 36.36 ± 0.03 |
| 72 hours | 36.30 ± 0.03 | 36.31 ± 0.03 |
| 96 hours | 36.26 ± 0.03 | 36.23 ± 0.03 |
| 120 hours | 36.27 ± 0.03 | 36.21 ± 0.03 |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
| hours | Baloxavir | Placebo |
|---|---|---|
| Cough | 38.3 (30.3 to 43.5) | 61.4 (44.8 to 69.5) |
| Sore Throat | 31.5 (27.3 to 39.2) | 40.5 (31.8 to 48.3) |
| Headache | 26.1 (22.9 to 29.8) | 37.9 (25.8 to 42.2) |
| Nasal Congestion | 31.8 (29.9 to 38.7) | 52.5 (41.5 to 62.7) |
| Feverishness or chills | 20.9 (20.0 to 21.9) | 25.8 (21.7 to 31.5) |
| Muscle or joint pain | 23.2 (21.4 to 26.3) | 31.3 (25.5 to 39.2) |
| Fatigue | 25.3 (22.0 to 29.2) | 40.5 (31.2 to 46.8) |
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Cough | 38.2 (30.3 to 43.4) | 31.4 (28.6 to 36.8) |
| Sore Throat | 32.1 (27.6 to 39.8) | 30.4 (25.0 to 43.9) |
| Headache | 26.9 (24.5 to 30.8) | 25.6 (21.9 to 30.4) |
| Nasal Congestion | 33.0 (30.5 to 40.4) | 31.3 (26.8 to 39.8) |
| Feverishness or chills | 21.0 (20.0 to 22.0) | 21.2 (20.3 to 22.0) |
| Muscle or joint pain | 23.3 (21.6 to 26.7) | 24.0 (21.6 to 27.1) |
| Fatigue | 28.9 (23.2 to 30.5) | 26.6 (23.0 to 30.8) |
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
| hours | Baloxavir | Placebo |
|---|---|---|
| Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo | 129.2 (122.1 to 152.3) | 168.8 (145.9 to 202.2) |
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and your health condition\]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
| hours | Baloxavir | Oseltamivir |
|---|---|---|
| Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir | 127.8 (121.5 to 152.8) | 128.5 (122.8 to 151.0) |
The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
| percentage of participants | Baloxavir | Placebo |
|---|---|---|
| Any complication | 3.5 (2.0 to 5.6) | 4.3 (2.1 to 7.8) |
| Death | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Hospitalization | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Sinusitis | 0.9 (0.2 to 2.2) | 0.9 (0.1 to 3.1) |
| Otitis media | 0.4 (0.1 to 1.6) | 0 (0.0 to 1.6) |
| Bronchitis | 2.0 (0.9 to 3.7) | 3.5 (1.5 to 6.7) |
| Pneumonia | 0.4 (0.1 to 1.6) | 0.4 (0.0 to 2.4) |
The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.
| percentage of participants | Baloxavir | Oseltamivir |
|---|---|---|
| Any complication | 4.0 (2.2 to 6.5) | 2.4 (1.1 to 4.5) |
| Death | 0 (0.0 to 1.0) | 0 (0.0 to 1.0) |
| Hospitalization | 0 (0.0 to 1.0) | 0.3 (0.0 to 1.5) |
| Sinusitis | 0.8 (0.2 to 2.3) | 0 (0.0 to 1.0) |
| Otitis media | 0.5 (0.1 to 1.9) | 0.3 (0.0 to 1.5) |
| Bronchitis | 2.4 (1.1 to 4.5) | 1.6 (0.6 to 3.4) |
| Pneumonia | 0.5 (0.1 to 1.9) | 0.3 (0.0 to 1.5) |
| percentage of participants | Baloxavir | Placebo | Oseltamivir |
|---|---|---|---|
| Adverse events (AEs) | 20.7 | 24.6 | 24.8 |
| Serious adverse events (SAEs) | 0.3 | 0.0 | 0.0 |
| AEs leading to withdrawal of study drug | 0.3 | 0.3 | 0.4 |
| Treatment-related adverse events (TRAEs) | 4.4 | 3.9 | 8.4 |
| Treatment-related serious adverse events | 0.0 | 0.0 | 0.0 |
| TRAEs leading to withdrawal of study drug | 0.0 | 0.3 | 0.2 |
Collected over From first dose of treatment to Day 22. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir | 0/610 (0%) | 2/610 (0.3%) | 47/610 (7.7%) |
| Placebo | 0/309 (0%) | 0/309 (0%) | 40/309 (12.9%) |
| Oseltamivir | 0/513 (0%) | 0/513 (0%) | 45/513 (8.8%) |
| Event | Baloxavir | Placebo | Oseltamivir |
|---|---|---|---|
| Meningitis viralInfections and infestations | 1/610 | 0/309 | 0/513 |
| Incarcerated inguinal herniaGastrointestinal disorders | 1/610 | 0/309 | 0/513 |
| Event | Baloxavir | Placebo | Oseltamivir |
|---|---|---|---|
| BronchitisInfections and infestations | 16/610 | 17/309 | 18/513 |
| DiarrhoeaGastrointestinal disorders | 18/610 | 14/309 | 11/513 |
| NauseaGastrointestinal disorders | 8/610 | 4/309 | 16/513 |
| SinusitisInfections and infestations | 7/610 | 8/309 | 5/513 |
Intention-to-treat infection (ITTI) population consisting of participants who received study drug with a confirmed diagnosis of influenza. Confirmation of influenza was based on the results of reverse transcription polymerase chain reaction (RT-PCR) on Day 1.
| Age, Continuous(Years) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Mean | 33.5 ± 13.5 | 33.9 ± 13.7 | 36.0 ± 11.8 | 34.5 ± 13.0 |
| Age, Customized(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| ≥ 12 to ≤ 19 years | 80 | 38 | 0 | 118 |
| ≥ 20 to ≤ 29 years | 121 | 61 | 134 | 316 |
| ≥ 30 to ≤ 39 years | 92 | 47 | 104 | 243 |
| ≥ 40 to ≤ 49 years | 97 | 48 | 77 | 222 |
| ≥ 50 to ≤ 59 years | 52 | 30 | 51 | 133 |
| ≥ 60 to ≤ 64 years | 14 | 7 | 11 | 32 |
| Sex: Female, Male(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Female | 224 | 111 | 159 | 494 |
| Male | 232 | 120 | 218 | 570 |
| Ethnicity (NIH/OMB)(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Hispanic or Latino | 32 | 11 | 25 | 68 |
| Not Hispanic or Latino | 424 | 220 | 352 | 996 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 349 | 178 | 305 | 832 |
| Black or African American | 18 | 11 | 9 | 38 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 85 | 40 | 60 | 185 |
| Other | 4 | 2 | 2 | 8 |
| Time From Symptom Onset to Initiation of the Trial Regimen(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| ≥ 0 to ≤ 12 hours | 60 | 34 | 41 | 135 |
| > 12 to ≤ 24 hours | 178 | 87 | 163 | 428 |
| > 24 to ≤ 36 hours | 139 | 67 | 94 | 300 |
| > 36 to ≤ 48 hours | 79 | 43 | 79 | 201 |
| Influenza Virus Type or Subtype on RT-PCR Assay at Enrollment(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| A/H1N1pdm | 7 | 7 | 2 | 16 |
| A/H3 | 393 | 196 | 332 | 921 |
| B | 38 | 20 | 34 | 92 |
| Mixed infection | 8 | 3 | 6 | 17 |
| Other | 10 | 5 | 3 | 18 |
| Region(Participants) | Baloxavir | Placebo | Oseltamivir | Total |
|---|---|---|---|---|
| Japan/Asia | 343 | 175 | 303 | 821 |
| Rest of the world | 113 | 56 | 74 | 243 |
1 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Apr 2017, 3 months.
Results were first posted in Dec 2018, 1 year 8 months after primary completion. A results delay was requested in Mar 2018.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 3 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir